Get the Stockscreener App
15.16
1.34%
0.20
After Hours:
15.14
-0.02
-0.13%
Range Cancer Therapeutics Etf stock is traded at $15.16, with a volume of 3,522.
It is up +1.34% in the last 24 hours and up +1.40% over the past month.
See More
Previous Close:
$14.96
Open:
$15.0086
24h Volume:
3,522
Relative Volume:
0.88
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.86%
1M Performance:
+1.40%
6M Performance:
-4.41%
1Y Performance:
+41.55%
1-Day Range:
$15.01
$15.16
1-Week Range:
$14.58
$15.16
52-Week Range:
$9.5201
$17.96
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Name
Range Cancer Therapeutics Etf
Sector
Industry
Phone
-
Address
-
Range Cancer Therapeutics Etf Stock (CNCR) Latest News
(CNCR) Trading Report - Stock Traders Daily
The 5 Best Biotech ETFs of 2024 - TradingView
(CNCR) Investment Report - Stock Traders Daily
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV - Yahoo Finance
4 Solid ETFs Under $20 for Your Portfolio - Yahoo Finance
(CNCR) Investment Analysis - Stock Traders Daily
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market (SMMT) - Seeking Alpha
7 Best-Performing Biotech ETFs for November 2024 - NerdWallet
Trackinsight ETF data from 23rd to 27th September, 2024 - ETF Express
(CNCR) Investment Analysis and Advice - Stock Traders Daily
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Roundhill Investments Surpasses $2 Billion AUM Milestone – Company Announcement - Financial Times
5 ETFs That Led the Rebound on Monday - Yahoo Finance
IPO Roundup: Bicara Therapeutics, Kairos Pharma and more (NYSEARCA:IPO) - Seeking Alpha
Trading (CNCR) With Integrated Risk Controls - Stock Traders Daily
Cellectis: Cheap With Promising But Speculative Cancer Therapies (NASDAQ:CLLS) - Seeking Alpha
Best-Performing ETF Areas of Past Week - MSN
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology (TCRX) - Seeking Alpha
Why It May Be 'Just Right' to Invest in Cancer Therapeutics Development Stocks Now - Nasdaq
3 Top-Ranked ETFs Under $20 for Your Portfolio - MSN
(CNCR) Long Term Investment Analysis - Stock Traders Daily
Invest in Hope, Invest in Life - Nasdaq
5 Top-Ranked ETFs to Buy at a Bargain - Yahoo Finance
Wall Street indexes rise after strong jobs data - Yahoo News Canada
VIXY Jumped 7.3% Last Week - Yahoo Finance
SPY Led Inflows Last Week as Leveraged Funds Surged - etf.com
Best ETFs of Last Week - Yahoo Finance
US stocks waver, extending tech-led selloff - Yahoo Singapore News
Time for Healthcare ETFs? - Yahoo Finance
TSLA-related ETFs among top performing ETFs on a 4-week performance base last week - MSN
5 Top ETFs of Last Week - Yahoo Finance
US consumer inflation eases more than expected - Yahoo Singapore News
How the (CNCR) price action is used to our Advantage - Stock Traders Daily
GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly - Yahoo Finance
All you need to know about: Malaysia’s new cost-of-living benchmark - Yahoo News Malaysia
HHLHarvest ETFs: Harvest Healthcare Leaders Income ETF - The Globe and Mail
Tesla: Should You Buy the Stock Before Firm’s Q2 Deliveries Report? - Investing.com
4 Up-and-Coming Small-Cap Biotech Stocks to Watch - Investing.com
S&P 500, Nasdaq close higher to kick off second half's trading: Live updates - CNBC
(CNCR) Proactive Strategies - Stock Traders Daily
Reviewing Replimune Group (NASDAQ:REPL) and Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
7 Best Biotech ETFs to Buy Now | Investing - U.S News & World Report Money
Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive (BDTX) - Seeking Alpha
How to Invest in the Semiconductor Value Chain with These ETFs - The Globe and Mail
BMO ETFs: Balancing Growth and Income - The Globe and Mail
Oncology Stocks: 8 Biggest NASDAQ Companies in 2024 | INN - Investing News Network
Where are the Opportunities in (CNCR) - Stock Traders Daily
Range Cancer Therapeutics Etf Stock (CNCR) Financials Data
There is no financial data for Range Cancer Therapeutics Etf (CNCR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):